The MOGAM Institute for Biomedical Research (MIBR), Korea’s first privately owned non-profit research institute, was established in 1984 by Dr. Young-sup Huh using all of the profit generated from the successful development of the Hepatitis B vaccine by Green Cross Pharmaceuticals. MIBR has made significant contributions to Korea’s biomedical industry by successfully producing vaccines, diagnostic kits, and important recombinant proteins. MIBR led to the development of the third in the world Hepatitis B vaccine, the first Epidemic hemorrhagic fever vaccine, and the second chickenpox vaccine. Our mission is to help those suffering from disease by understanding life’s underlying cellular and molecular processes and using this knowledge to develop innovative therapies. The MIBR is the place for creative thought and collaboration to bridge between academic institutions and industry.